BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock

$2.91

2.11% yesterday

Nasdaq, May 16, 10:00 pm CET

ISIN

US09073Q1058

Symbol

SCNI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock price

$2.91

-1,843.09 99.84% 5Y

Nasdaq, Closing price Fri, May 16 2025

+0.06 2.11%

ISIN

US09073Q1058

Symbol

SCNI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$2.48m
Enterprise Value	$8.11m
P/E (TTM) P/E ratio	1.06
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	12.29
P/S ratio (TTM) P/S ratio	3.76
P/B ratio (TTM) P/B ratio	0.57
Revenue (TTM) Revenue	$660.00k
EBIT (operating result TTM) EBIT	$-8.68m
Free Cash Flow (TTM) Free Cash Flow	$-6.38m
Cash position	$2.09m
EPS (TTM) EPS	$2.74
Short interest	1.75%

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Get Started for Free Today

BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast BiondVax Pharmaceuticals Ltd. Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast BiondVax Pharmaceuticals Ltd. Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from BiondVax Pharmaceuticals Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	0.66 0.66	- 100%
- Direct Costs	2.89 2.89	681% 681% 438%
Gross Profit	-2.24 -2.24	- -339%
- Selling and Administrative Expenses	-	-
- Research and Development Expense	5.56 5.56	7% 7% 842%
EBITDA	-7.02 -7.02	23% 23% -1,064%
- Depreciation and Amortization	1.65 1.65	- 250%
EBIT (Operating Income) EBIT	-8.68 -8.68	10% 10% -1,315%
Net Profit	3.74 3.74	158% 158% 567%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock News

Neutral

PRNewsWire

●

10 days ago

Scinai Announces Annual Financial Results for 2024

JERUSALEM , May 7, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its annual financi...

Neutral

PRNewsWire

●

16 days ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). JERUSALEM, Israel , May 1, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.

Neutral

PRNewsWire

●

about 2 months ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's Agency An application will be filed with the FDA for Orphan Drug a...

More BiondVax Pharmaceuticals Ltd. Sponsored ADR News

Company Profile

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.

Head office	Israel
CEO	Amir Reichman
Employees	31
Founded	2003
Website	www.scinai.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now